Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that hVIVO
Open Orphan PLC (ORPH.L) £1.5m Contract renewal for Venn Life Sciences
£1.5m Contract renewal for Venn Life Sciences with a major global pharmaceutical client
Open Orphan PLC (ORPH.L) Directorate Change
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces the appointment
How one company is testing vaccines through intentional infection
Open Orphan Executive Chairman Cathal Friel joins Yahoo Finance Live to discuss how his company is testing vaccines through intentional infection.
Open Orphan PLC (ORPH.L) £5.7m Influenza human challenge study contract win
Open Orphan plc (AIM: ORPH), a rapidly growing specialist clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that hVIVO
Open Orphan PLC (ORPH.L) Notice of Interim Results
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that its
Open Orphan PLC (ORPH.L) Positive results from RSV Human Challenge Study
RSV Human Challenge Study conducted by hVIVO yields positive results
Open Orphan PLC (ORPH.L) £8.1m Asthma Human Challenge Study Contract Win
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that hVIVO
Open Orphan PLC (ORPH.L) Malaria Human Challenge Model
Development of Controlled Human Malaria Infection Human Challenge Study hVIVO to assist in the advancement of antimalarial drug and vaccine candidates from November 2021
Open Orphan PLC (ORPH.L) DNDi Phase II trial support
Contract to support Phase II river blindness drug trial Antibiotic drug study for the treatment of the second-most common cause of blindness due to infection
Open Orphan PLC (ORPH.L) NEJM Opinion Piece
The New England Journal of Medicine (NEJM) publishes editorial relating to Human Challenge Programme
Poolbeg Pharma PLC (POLB.L) Admission to AIM
First day of trading